Tamoxifen is a selective ER modifier that reduces the BC recurrence rate to 40%–50% and showed clinically profound impacts in lowering death rates (Karn, Jha, Shrestha, Acharya, et al., 2010). Here, ESR1 is linked to breast cancer.